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To the editor:
Fabry disease is a rare X-linked lysosomal storage disorder caused by
mutations in the GLA gene that result in functional deficiency of alpha-
galactosidase A (α-Gal A); the accumulation of lysosomal α-Gal A sub-
strates can lead to multisystem disease and early death (Germain, 2010;
Mehta et al., 2010; Waldek, Patel, Banikazemi, Lemay, & Lee, 2009).
Until recently, treatment options were limited to enzyme replacement
therapy (ERT) with agalsidase alfa or agalsidase beta administered via
infusion every 2 weeks (Gaggl & Sunder-Plassmann, 2016).
Migalastat is a first-in-class, small-molecule pharmacological chaper-
one that binds to and stabilizes amenable mutant forms of α-Gal A in
the endoplasmic reticulum, facilitating proper trafficking to lysosomes,
where dissociation of migalastat allows α-galactosidase to catabolize
accumulated substrates (Benjamin et al., 2009; Germain et al., 2016;
Germain & Fan, 2009; Ishii et al., 2007; Khanna et al., 2010; Yam,
Zuber, & Roth, 2005). It is estimated that 35–50% of patients with Fabry
disease have migalastat-amenable mutations (Hughes et al., 2017). As
of July 23, 2018, the total exposure to migalastat in the Phase 2 and 3
clinical programs was 660 patient-years, with 128 patients exposed
≥1 year (Data on file. Amicus Therapeutics Inc., 2018). The efficacy
and safety of migalastat in patients with Fabry disease who have amena-
ble GLA mutations have been established in both placebo and active-
controlled clinical trials and long-term open-label extension studies
(Germain et al., 2016; Germain et al., 2018; Hughes et al., 2017; Nicholls
et al., 2018). Oral migalastat has been approved in the European Union,
Switzerland, Australia, Israel, Republic of Korea, and Japan for long-term
treatment of adults and adolescents aged 16 years and older with a con-
firmed diagnosis of Fabry disease (α-Gal A deficiency) who have a
migalastat-amenable GLA mutation (Amicus Therapeutics Inc., 2018).
Migalastat is also approved in the United States and Canada for adults
(aged 18 years and older; Amicus Therapeutics U.S., Inc., 2018; Amicus
Therapeutics UK Ltd., 2017).
We previously reported on Part 1 of the Phase 3 ATTRACT study
(AT1001-012; NCT01218659), an 18-month randomized treatment†Deceased December 19, 2017.
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comparison that demonstrated comparable efficacy of migalastat
(Cohort 1) and ERT (Cohort 2) in male and female patients with Fabry
disease previously treated with ERT for >12 months (Hughes et al.,
2017). During Part 2 of the ATTRACT study, patients in both cohorts
could receive migalastat for an additional 12 months during the
optional open-label extension (OLE). Therefore, both cohorts switched
from ERT to migalastat (at baseline for patients randomized at study
entry to migalastat [Cohort 1] or month 18 for those randomized to
ERT [Cohort 2]). In this article, we assess the safety of switching from
ERT to migalastat by evaluating the incidence of adverse events, labo-
ratory assessments, and concomitant medications following switching
in both cohorts within the safety population.
At study entry, patients ranged in age from 18 to 72 years with a
mean age of 49 years; 56% were female (Hughes et al., 2017). Demo-
graphics were balanced between cohorts. Mean time since Fabry diag-
nosis was 11.4 years, and most patients (88%) had multi-organ
disease (including nervous system [81%], cardiac [71%], gastrointesti-
nal [61%], and renal/urinary [75%] involvement (Hughes et al., 2017);
renal/urinary involvement was defined as having any of the following:
a medical history of renal or urinary disorders, decreased estimated
glomerular filtration rate (eGFR <90 mL/min/1.73 m2; ~44% of adults
aged 40 to 59 have an eGFR below this cutoff [National Kidney Foun-
dation, 2002]), or 24-hr urine protein ≥150 mg). Eight patients had a
history of premedication for ERT infusion-associated reactions (IARs;
n = 5 in Cohort 1; n = 3 in Cohort 2); 2 patients in Cohort 2 continued
IAR prophylaxis during on-study ERT. Fifty-one patients switched from
ERT to migalastat: 36 patients in Cohort 1 (Part 1) and 15 patients in
Cohort 2 (Part 2/OLE). Most patients continued migalastat treatment
until Month 30 (30/36 in Cohort 1 and 12/15 in Cohort 2).
Cohort 1 patients switched to migalastat treatment at baseline, by
which time most patients had received >2 years of ERT (mean, 3.5 years;
Table 1). Prior ERT characteristics were similar between male and female
patients. In patients for whom the data were available, migalastat was
started 4 to 19 days after their last ERT infusion. The most common
treatment-emergent adverse events (AEs) in Cohort 1 (occurring in
≥20% of patients) during the first 18 months were nasopharyngitis
(33%) and headache (25%; Table 2), and during the full 30 months were
nasopharyngitis (42%), headache (36%), and influenza (27%; Table 2).
AEs were generally mild or moderate; no patient discontinued due to
an AE. There were no clinically meaningful changes in mean values
from baseline for hematology, serum chemistry, urinalysis analysis, and
vital signs (Supporting Information Table S1). Thirty-four (94%) Cohort
1 patients started a new medication during months 0–30. The most
common new concomitant mediations were amoxicillin (22%), ibuprofen
(19%), paracetamol (19%), amoxicillin with clavulanic acid (11%), and
temazepam (11%). Only two (6%) patients started a new angiotensin-
converting enzyme inhibitor, angiotensin II receptor blocker, or renin
inhibitor. Overall, based on a review of AEs, laboratory measures, and
concomitant medications in Cohort 1, migalastat was well tolerated after
patients switched from ERT.
Cohort 2 patients switched treatment at Month 18, after most
patients completed >3 years of ERT (mean, 5.2 years; Table 1). Naso-
pharyngitis (33%), headache (24%), and cough (24%) were the most com-
mon AEs during the 18-month ERT treatment period in Part 1 (Table 3).
In patients for whom the data were available, migalastat was started 2 to
14 days after their last ERT infusion. The most common AEs during
12 months of migalastat treatment in Part 2 were nasopharyngitis (33%),
diarrhea (27%), vomiting (27%), influenza (20%), and headache (20%;
Table 3). Although the percentages of patients experiencing diarrhea or
vomiting increased after the switch to migalastat, these reflect changes
in only 1–2 patients and the small patient numbers limit interpretation.
There were no clinically meaningful changes in mean values from hema-
tology, serum chemistry, urinalysis analysis, and vital signs following
the switch from ERT to migalastat (Supporting Information Table S2).
Twelve (80%) Cohort 2 patients started a new medication during months
18–30. The most common new concomitant medications were general
TABLE 1 Enzyme replacement therapy characteristics prior to start of Migalastat
Cohort 1a Cohort 2b
Female Male Overall Female Male Overall
ERT at baseline, n (%)
Agalsidase beta 6 (30.0) 5 (31.3) 11 (30.6) 5 (50.0) 0 5 (33.3)
Agalsidase alfa 14 (70.0) 10 (62.5) 24 (66.7) 5 (50.0) 5 (100.0) 10 (66.7)
Missing 0 1 (6.3) 1 (2.8) 0 0 0
ERT duration, years
N 17 12 29 10 5 15
Mean ± SD 3.0 ± 2.1 4.2 ± 3.7 3.5 ± 2.9 4.9 ± 3.0 6.0 ± 3.1 5.2 ± 3.0
Median 2.2 2.8 2.3 3.6 6.9 3.6
(min, max) (1.0, 8.4) (0.4, 12) (0.4, 12) (1.3, 10) (2.3, 9.9) (1.3, 10)
ERT duration, n (%)
<2 years 6 (30.0) 3 (18.8) 9 (25.0) 2 (20.0) 0 2 (13.3)
2 to 3 years 7 (35.0) 3 (18.8) 10 (27.8) 0 1 (20.0) 1 (6.7)
3 to 4 years 1 (5.0) 2 (12.5) 3 (8.3) 4 (40.0) 1 (20.0) 5 (33.3)
>4 years 3 (15.0) 4 (25.0) 7 (19.4) 4 (40.0) 3 (60.0) 7 (46.7)
Missing 3 (15.0) 4 (25.0) 7 (19.4) 0 0 0
Note. ERT = enzyme replacement therapy; max = maximum; min = minimum; n = number of patients with data; SD = standard deviation.
aThirty-six patients who were randomized to receive migalastat treatment.
bFor Cohort 2, only patients in the open-label extension phase were included.
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anesthetics (13%), clindamycin (13%), ibuprofen (13%), naproxen (13%),
and paracetamol (13%). Only 1 (7%) patient started a new angiotensin-
converting enzyme inhibitor, angiotensin II receptor blocker, or renin
inhibitor. Review of AEs, laboratory measures, and concomitant medica-
tions in Cohort 2 did not identify notable safety concerns after switching
to migalastat.
These data demonstrated a favorable safety profile after patients
directly switched to migalastat 150 mg QOD 2 to 19 days following their
last ERT infusion. Migalastat was generally well tolerated, and no patients
discontinued treatment due to AEs. Reason for discontinuing ERT during
0–18 months was withdrawal by participant (n = 3); reasons for disconti-
nuing migalastat during 0–30 months were withdrawal by participant
(n = 4), pregnancy (n = 1), lack of efficacy (n = 1), physician decision
unrelated to migalastat (n = 1), and lost to follow-up (n = 1).
Limitations of the analysis include the relatively small number of
patients who switched from agalsidase beta to migalastat, as most
(67%) patients switched from agalsidase alfa because enrollment for
ATTRACT coincided with the worldwide shortage of agalsidase beta.
Migalastat is the only oral treatment for Fabry disease, which pro-
vides a suitable alternative to once-every-2-weeks intravenous ERT in
patients with amenable mutations who are ERT-experienced and can
also be utilized as a first-line therapy in ERT-naive patients. Although
there has not yet been a consensus among physicians who treat patients
with Fabry disease on when to choose migalastat over ERT, we have
developed some criteria in our clinical practices, which include: age
16 years and older (18 years and older in the United States and Canada),
a confirmed amenable mutation, an eGFR > 30 mL/min/1.73 m2, com-
pliance with every-other-day oral administration, and no intention by
TABLE 3 Treatment-emergent adverse events occurring in ≥10% of
cohort 2 (ERT-Migalastat) patients
AE (preferred
term), n (%)
Part 1: ERT
(0–18
months)a
(n = 21)b
Part 2:
Migalastat
(18–30 months)c
(n = 15)d
Nasopharyngitis 7 (33) 5 (33)
Diarrhea 2 (10) 4 (27)
Vomiting 3 (14) 4 (27)
Headache 5 (24) 3 (20)
Influenza 4 (19) 3 (20)
Abdominal pain 2 (10) 2 (13)
Arthralgia 2 (10) 2 (13)
Bronchitis 3 (14) 2 (13)
Dizziness 2 (10) 2 (13)
Nausea 2 (10) 2 (13)
Blood creatine
phosphokinase
increased
1 (5) 2 (13)
Fatigue 1 (5) 2 (13)
Neuralgia 1 (5) 2 (13)
Pyrexia 1 (5) 2 (13)
Diabetes mellitus 0 2 (13)
Muscle spasm 0 2 (13)
Poor quality sleep 0 2 (13)
Cough 5 (24) 1 (7)
Back pain 3 (14) 1 (7)
Dyspnea 2 (10) 1 (7)
Pain in extremity 2 (10) 1 (7)
Sinusitis 3 (14) 0
Dry mouth 2 (10) 0
Gastritis 2 (10) 0
Peripheral edema 2 (10) 0
Procedural pain 2 (10) 0
Vertigo 2 (10) 0
Note. AE = adverse event; ERT = enzyme replacement therapy; OLE =
open-label extension.
aAny adverse events that started after first study drug administration and
before OLE first dose date.
bNumber of patients who had at least one dose of ERT during the study.
Eighteen patients completed treatment through 18 months (Part 1); the
reason for discontinuation during Part 1 was withdrawal by partici-
pant (n = 3).
cAny adverse events that started on or after randomized treatment period
first dose date up to 30 days after OLE last dose date.
dNumber of patients who had at least one dose of migalastat during Part
2. Twelve patients completed treatment through 30 months (Part 2). Rea-
sons for discontinuation during Part 2 include withdrawal by participant
(n = 1), physician decision (n = 1), lost to follow-up (n = 1).
TABLE 2 Treatment-emergent adverse events occurring in ≥10% of
Cohort 1 (Migalastat-Migalastat) patients
AE (preferred term), n (%)
Part 1: Migalastat
(0–18 months)d
(n = 36)a
Parts 1 and 2:
Migalastat (0–30
months)b (n = 33)c
Nasopharyngitis 12 (33) 14 (42)
Headache 9 (25) 12 (36)
Influenza 5 (14) 9 (27)
Cough 3 (8) 6 (18)
Diarrhea 5 (14) 6 (18)
Nausea 5 (14) 6 (18)
Dizziness 6 (17) 5 (15)
Abdominal pain 5 (14) 5 (15)
Urinary tract infection 4 (11) 5 (15)
Blood creatine
phosphokinase
increased
3 (8) 5 (15)
Myalgia 3 (8) 5 (15)
Arthralgia 3 (8) 4 (12)
Pyrexia 3 (8) 4 (12)
Sinusitis 3 (8) 4 (12)
Vomiting 3 (8) 4 (12)
Protein urine present 3 (8) 4 (12)
Pain 1 (3) 4 (12)
Back pain 4 (11) 3 (9)
Upper respiratory
tract infection
4 (11) 3 (9)
Note. AE = adverse event; OLE = open-label extension.
aNumber of patients who had at least one dose of migalastat during Part 1.
Thirty-four patients completed treatment through 18 months (Part 1). The
reason for discontinuation during Part 1 was withdrawal by partici-
pant (n = 2).
bAny adverse events that started on or after randomized treatment period
first dose date up to 30 days after OLE last dose date.
cNumber of patients who had at least one dose of migalastat during Part 2.
Thirty patients completed treatment through 30 months (Part 2). Reasons
for discontinuation during Part 2 include withdrawal by participant (n = 1),
pregnancy (n = 1), and lack of efficacy (n = 1).
dAny adverse events that started after first study drug administration and
before OLE first dose date.
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female patients to become pregnant. Patients' preference and hypersen-
sitivity to ERT are also factors in considering the best treatment option
for patients. We suggest having a comprehensive counseling session
with the patient to discuss the mechanism of action, clinical data, and
approved indication for migalastat, as well as schedule of administration.
For patients switching from ERT, migalastat is commonly initiated
~2 weeks after the last dose of ERT based on the infusion interval; how-
ever, other practical considerations may influence the exact duration
between the last ERT infusion and first dose of migalastat. Migalastat
may be safely initiated within days of the last ERT infusion.
In conclusion, patients with amenable mutations who have been
receiving ERT infusions can be safely switched to migalastat 150 mg
QOD, and no special procedure is needed for the switch.
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